Cardiometabolic programs move into large scale clinical…

Trial WatchCardiometabolicFactor XIPhase 3

Cardiometabolic programs move into large scale clinical testing

Edition 14 shows continued sponsor activity across cardiovascular, liver health and metabolic programs.

Cardiometabolic is one of the strongest areas in Trial Watch Edition 14.

This category includes multiple large clinical programs across cardiovascular care, liver health and long term metabolic treatment.

The largest program in this group is a major Phase 3 study with more than 15,000 participants, showing the scale of investment now moving into cardiometabolic development.

Other programs in this category also reflect a broader trend. Sponsors are continuing to test therapies in larger patient groups, longer study designs and more competitive treatment areas.

5 Cardiometabolic Trials

4 Phase 3 Programs

Largest Trial

Enrollment15,364 Participants

FXI Program Scale

Total Patients24,000 plus

MASH Program

NEBULA 11,740 Participants

Obesity Extension

MariTide3,200 Participants

Key Takeaway

Cardiometabolic development in Edition 14 is defined by larger studies, stronger sponsor commitment and continued activity across high demand treatment areas.

Read The Full Trial Watch